Meisoindigo for the treatment of chronic myelogenous leukaemia

被引：31

作者：

Xiao, ZJ ^{[1
]}

Qian, LS ^{[1
]}

Liu, BC ^{[1
]}

Hao, YS ^{[1
]}

机构：

[1] Chinese Acad Med Sci, Inst Haematol, Dept Clin Haematol, Tianjin 300020, Peoples R China

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2000年 / 111卷 / 02期

关键词：

chronic myelogenous leukaemia; treatment; meisoindigo;

D O I：

10.1046/j.1365-2141.2000.02357.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：711 / 712

页数：2

共 5 条

[1]

*COOP GROUP CLIN T, 1988, CHIN J HEMATOL, V9, P135

[2]

*COOP GROUP PHAS 3, 1997, CHIN J HEMATOL, V18, P69

[3] Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases [J].

Hoessel, R ;

Leclerc, S ;

Endicott, JA ;

Nobel, MEM ;

Lawrie, A ;

Tunnah, P ;

Leost, M ;

Damiens, E ;

Marie, D ;

Marko, D ;

Niederberger, E ;

Tang, WC ;

Eisenbrand, G ;

Meijer, L .

NATURE CELL BIOLOGY, 1999, 1 (01) :60-67

[4]

JI XJ, 1985, ACTA PHARMACOL SIN, V20, P247

[5] Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia [J].

O'Brien, S ;

Kantarjian, H ;

Koller, C ;

Feldman, E ;

Beran, M ;

Andreeff, M ;

Giralt, S ;

Cheson, B ;

Keating, M ;

Freireich, E ;

Rios, MB ;

Talpaz, M .

BLOOD, 1999, 93 (12) :4149-4153

← 1 →